US FDA consults on lowering risk classification level of implanted blood access devices
This article was originally published in Clinica
The US Food and Drug Administration is inviting stakeholder feedback on its proposal to lower the risk classification level of implanted blood access devices, from Class III to Class II with special controls.
You may also be interested in...
The European Court of Justice has confirmed the European Medicines Agency’s approach to disclosure of data submitted as part of a marketing authorization application. It is a big disappointment for industry, which nonetheless says it supports responsible data sharing and will support efforts to develop a balanced approach.
An EU pilot project will assess whether there is sufficient demand from companies to obtain simultaneous scientific advice from EU national competent authorities.
An ambitious action plan drawn by an EU task force, if implemented on a priority basis by the European Commission, could increase the EU’s capacity to advise on, assess and analyze big data.